Sex |
|
|
Male |
20 |
64.5 |
Female |
11 |
35.5 |
Age: years, median (range) |
52 (25-73) |
|
Karnofsky Performance Status: median (range) |
80(60-90) |
|
Pathologic types |
|
|
Non-keratinizing |
17 |
54.8 |
Squamous cell carcinoma |
14 |
45.2 |
Previous EBRT frequency |
|
|
Once |
20 |
64.5 |
Two times |
9 |
29.0 |
Three times |
2 |
6.5 |
Total dose of previous EBRT: Median (Range) |
71.9 (60-160) |
|
Previous surgery |
|
|
Yes |
7 |
22.6 |
No |
23 |
74.2 |
Not known |
1 |
3.2 |
Previous chemotherapy |
|
|
Yes |
23 |
74.2 |
No |
8 |
25.8 |
Previous molecular targeted therapy |
|
|
Yes |
7 |
22.6 |
No |
24 |
77.4 |
Recurrent sites |
|
|
In situ |
14 |
45.2 |
Lymph node |
17 |
54.8 |
Time from the initial EBRT to implantation: months, median
(range) |
19.6(2.1-113.3) |
|